REG - Goldman Sachs & Co. Avadel Pharma plc - ITP Only - (38.5b) AVADEL PHARMACEUTICALS PLC
Mon 11:00
For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260105:nRSE6581Na&default-theme=true
RNS Number : 6581N Goldman Sachs & Co. LLC 05 January 2026
FORM 38.5(b)
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 38.5(b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITHOUT RECOGNISED INTERMEDIARY STATUS, OR WITH RECOGNISED INTERMEDIARY STATUS BUT NOT DEALING IN A CLIENT-SERVING CAPACITY
1. KEY INFORMATION
Name of exempt principal trader GOLDMAN SACHS & CO. LLC
Company dealt in AVADEL PHARMACEUTICALS PLC
Class of relevant security to which the dealings being disclosed relate USD 0.01 ordinary shares
(Note1)
Date of dealing 02 January 2026
2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 2)
Long Short
Number (%) Number (%)
(1) Relevant securities 669,210 (0.68) 479,715 (0.49)
(2) Derivatives (other than options) 39,256 (0.04) 63,843 (0.06)
(3) Options and agreements to purchase/sell 0 (0.00) 0 (0.00)
Total 708,466 (0.72) 543,558 (0.55)
(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 2)
Class of relevant security: Long Short
Number (%) Number (%)
(1) Relevant securities
(2) Derivatives (other than options)
(3) Options and agreements to purchase/sell
Total
3. DEALINGS (Note 3)
(a) Purchases and sales
Purchase/sale Number of relevant securities Price per unit (Note 4)
Purchase 4 21.5100 USD
Purchase 3 21.5100 USD
Purchase 14 21.5140 USD
Purchase 16 21.5140 USD
Purchase 16 21.5140 USD
Purchase 13 21.5144 USD
Purchase 67 21.5145 USD
Purchase 10 21.5150 USD
Purchase 20 21.5200 USD
Purchase 16 21.5200 USD
Purchase 11 21.5200 USD
Purchase 16 21.5200 USD
Purchase 8 21.5200 USD
Purchase 9 21.5200 USD
Purchase 16 21.5200 USD
Purchase 14 21.5227 USD
Purchase 21 21.5250 USD
Purchase 19 21.5250 USD
Purchase 12 21.5250 USD
Purchase 9 21.5250 USD
Purchase 8 21.5300 USD
Purchase 9 21.5300 USD
Sale 8 21.4810 USD
Sale 8 21.4822 USD
Sale 13 21.4842 USD
Sale 6 21.4842 USD
Sale 8 21.4842 USD
Sale 8 21.4842 USD
Sale 6 21.4844 USD
Sale 9 21.4847 USD
Sale 8 21.4847 USD
Sale 3 21.4848 USD
Sale 15 21.4850 USD
Sale 2 21.4850 USD
Sale 2 21.4850 USD
Sale 8 21.4850 USD
Sale 7 21.4850 USD
Sale 8 21.4850 USD
Sale 3 21.4850 USD
Sale 2 21.4850 USD
Sale 2 21.4850 USD
Sale 9 21.4853 USD
Sale 2 21.4855 USD
Sale 2 21.4855 USD
Sale 2 21.4855 USD
Sale 3 21.4859 USD
Sale 9 21.4859 USD
Sale 7 21.4861 USD
Sale 8 21.4862 USD
Sale 9 21.4863 USD
Sale 11 21.4864 USD
Sale 12 21.4864 USD
Sale 10 21.4865 USD
Sale 9 21.4866 USD
Sale 3 21.4866 USD
Sale 8 21.4866 USD
Sale 18 21.4866 USD
Sale 18 21.4866 USD
Sale 2 21.4868 USD
Sale 9 21.4870 USD
Sale 16 21.4870 USD
Sale 10 21.4870 USD
Sale 2 21.4871 USD
Sale 8 21.4871 USD
Sale 3 21.4872 USD
Sale 15 21.4874 USD
Sale 15 21.4875 USD
Sale 13 21.4879 USD
Sale 9 21.4881 USD
Sale 11 21.4885 USD
Sale 10 21.4885 USD
Sale 10 21.4886 USD
Sale 11 21.4887 USD
Sale 17 21.4892 USD
Sale 9 21.4906 USD
Sale 3 21.4907 USD
Sale 14 21.4908 USD
Sale 2 21.4912 USD
Sale 2 21.4912 USD
Sale 2 21.4912 USD
Sale 19 21.4915 USD
Sale 2 21.4918 USD
Sale 2 21.4921 USD
Sale 3 21.4923 USD
Sale 2 21.4923 USD
Sale 22 21.4927 USD
Sale 9 21.4936 USD
Sale 3 21.4937 USD
Sale 3 21.4937 USD
Sale 4 21.4938 USD
Sale 2 21.4938 USD
Sale 3 21.4938 USD
Sale 2 21.4939 USD
Sale 2 21.4940 USD
Sale 26 21.4940 USD
Sale 2 21.4942 USD
Sale 12 21.4944 USD
Sale 12 21.4945 USD
Sale 9 21.4946 USD
Sale 2 21.4946 USD
Sale 12 21.4947 USD
Sale 2 21.4947 USD
Sale 11 21.4949 USD
Sale 2 21.4949 USD
Sale 2 21.4949 USD
Sale 3 21.4950 USD
Sale 12 21.4950 USD
Sale 3 21.4950 USD
Sale 3 21.4950 USD
Sale 11 21.4950 USD
Sale 2 21.4950 USD
Sale 3 21.4950 USD
Sale 3 21.4950 USD
Sale 11 21.4950 USD
Sale 3 21.4950 USD
Sale 11 21.4951 USD
Sale 3 21.4951 USD
Sale 3 21.4952 USD
Sale 11 21.4953 USD
Sale 8 21.4953 USD
Sale 26 21.4953 USD
Sale 3 21.4954 USD
Sale 9 21.4955 USD
Sale 3 21.4955 USD
Sale 3 21.4955 USD
Sale 38 21.4977 USD
Sale 12 21.4982 USD
Sale 9 21.4987 USD
Sale 11 21.4991 USD
Sale 75 21.4995 USD
Sale 3 21.5000 USD
Sale 2 21.5000 USD
Sale 1 21.5000 USD
Sale 3 21.5001 USD
Sale 14 21.5001 USD
Sale 6 21.5002 USD
Sale 9 21.5002 USD
Sale 3 21.5002 USD
Sale 3 21.5003 USD
Sale 3 21.5003 USD
Sale 10 21.5004 USD
Sale 3 21.5004 USD
Sale 3 21.5004 USD
Sale 3 21.5004 USD
Sale 10 21.5004 USD
Sale 14 21.5005 USD
Sale 9 21.5005 USD
Sale 14 21.5005 USD
Sale 14 21.5006 USD
Sale 3 21.5009 USD
Sale 14 21.5012 USD
Sale 3 21.5020 USD
Sale 3 21.5020 USD
Sale 3 21.5026 USD
Sale 14 21.5027 USD
Sale 3 21.5030 USD
Sale 5 21.5030 USD
Sale 10 21.5036 USD
Sale 3 21.5037 USD
Sale 14 21.5038 USD
Sale 14 21.5041 USD
Sale 14 21.5047 USD
Sale 13 21.5047 USD
Sale 14 21.5047 USD
Sale 14 21.5049 USD
Sale 14 21.5051 USD
Sale 310 21.5200 USD
Sale (Borrow Partial Return) 3,200 N/A
Sale (Borrow Full Return) 17,300 N/A
Sale (Borrow Partial Return) 17,100 N/A
Purchase (Borrow New) 39,200 N/A
(b) Derivatives transactions (other than options transactions)
Product name, e.g. CFD Nature of transaction (Note 5) Number of relevant securities (Note 6) Price per unit (Note 4)
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
Product name,e.g. call option Writing, selling, purchasing, varying etc. Number of securities to which the option relates (Note 7) Exercise price Type, e.g. American, European etc. Expiry date Option money paid/received per unit (Note 4)
(ii) Exercising
Product name,e.g. call option Number of securities Exercise price per unit (Note 4)
(d) Other dealings (including transactions in respect of new securities) (Note 3)
Nature of transaction (Note 7) Details Price per unit (if applicable) (Note 4)
4. OTHER INFORMATION
Agreements, arrangements or understandings relating to options or derivatives
Full details of any agreement, arrangement or understanding between the person
disclosing and any other person relating to the voting rights of any relevant
securities under any option referred to on this form or relating to the voting
rights or future acquisition or disposal of any relevant securities to which
any derivative referred to on this form is referenced. If none, this should
be stated.
NONE
Is a Supplemental Form 8 attached? (Note 9) YES
Date of disclosure 05 January 2026
Contact name Papa Lette and Andrzej Szyszka
Telephone number +33(1) 4212 1459 / +48(22) 317 4817
Name of offeree/offeror with which connected AVADEL PHARMACEUTICALS PLC
Nature of connection (Note 9) Advisor to Offeree
SUPPLEMENTAL FORM 38.5(b)
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 38.5(b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
DETAILS OF OPEN POSITIONS
OPEN POSITIONS (Note 1)
Product name,e.g. call option Written or purchased Number of relevant securities to which the option or derivative relates Exercise price (Note 2) Type, e.g. American, European etc. Expiry date
Swap Sold 84 0.0000 N/A 13/03/2026
Swap Purchased 33,762 0.0000 N/A 20/01/2026
Notes
1. Where there are open option positions or open derivative positions (except
for CFDs), full details should be given. Full details of any existing
agreements to purchase or to sell must also be given on this form.
2. For all prices and other monetary amounts, the currency must be stated.
For full details of disclosure requirements, see Rules 8 and 38.5 of the
Rules. If in doubt, consult the Panel.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END ITPFIFEALSIEIIR
Copyright 2019 Regulatory News Service, all rights reservedRecent news on Goldman Sachs
See all newsREG - Goldman Sachs (EPT) Avadel Pharma plc - Form- (38.5b) AVADEL PHARMACEUTICALS PLC
AnnouncementREG - Goldman Sachs & Co. Avadel Pharma plc - Form 38.5(b) AVADEL PHARMACEUTICALS PLC
AnnouncementREG - J.P. Morgan Sec PLC Saudi Arabia (The) - Stabilisation Notice
AnnouncementREG - Deutsche Bank AG FF - Pre Stabilisation Notice - Israel USD 5/10/30yr
AnnouncementREG - Stock Exch Notice - Admission to Trading - 06/01/2026
Announcement